Clinical Trial Update: Single Ascending Dose Study of PRX002 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 single ascending dose study of PRX002 in healthy subjects by Prothena completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PRX002

Snippet

Sponsor: Prothena Biosciences Limited | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED